IL1B and cancer: There is a growing area of research asserting that cancer- and cancer-treatment related fatigue is driven by pro-inflammatory cytokines (e.g., IL-6, IL-1β, TNF-α) and inflammatory pathways (e.g., CRP, IL-1RA) as observed using animal [13,14] and clinical models [6,15].